Digital Pharma: NICE puts guidance into online pathways
pharmafile | May 11, 2011 | News story | Sales and Marketing | Digital Pharma blog, NICE
NICE has launched a new online tool that groups its guidance into user-friendly flowcharts to show care pathways.
NICE Pathways is aimed primarily at health and social care professionals and will offer an at-a-glance view of all the Institute’s guidance on a specific condition, such as diabetes or breast cancer.
It comes as the Institute prepares to see its guidance, and its single health technology assessments in particular, downgraded to advice to allow cost-effectiveness judgments to be made by value-based pricing.
The new site brings clarity to the different types of NICE advice by grouping its full range of health technology appraisals, clinical guidelines, public health and social care advice, quality standards and implementation tools together in place.
Dr Gillian Leng, NICE deputy chief executive and chief operating officer for NHS Evidence, said: “NICE pathways will provide a useful starting point for users new to a topic, whilst giving specialists confidence that they are up to date with everything NICE has recommended.
“This is an important part of a bigger picture to fully digitise our guidance and resources that will eventually result in our guidance being available through enhanced Internet access and mobile devices.”
The next steps will be to introduce full text searching and then links from NICE Pathways to the evidence used to develop its guidance.
“We also anticipate that third-party providers of information will be able to use our products in applications such as decision support systems,” Dr Leng added.
NICE Pathways launches with 18 pathways, containing around 90 pieces of guidance, based on its quality standards work.
The first pathways are for: alcohol-use disorders, anaemia management in chronic kidney disease, breast cancer, chronic heart failure, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), dementia, depression, diabetes, diabetes in pregnancy, diet, glaucoma, neonatal jaundice, physical activity, postnatal care, smoking, stroke, and venous thromboembolism (VTE) prevention
Although meant mainly for healthcare professionals, NICE says NICE Pathways will also be useful for public health experts, those who commission or use health and social care services, employers and members of the public.
Dominic Tyer is web editor for Pharmafocus and InPharm.com and the author of the Digital Pharma blog He can be contacted via email, Twitter or LinkedIn.
Related Content
Digital mental health technologies – a valuable tool in supporting people with depression and anxiety
The potential benefits of digital mental health technology for managing depression, anxiety and stress, together …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
